Browse
Submit Data
Databases
API
Help

Dataset Information

1 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease

ABSTRACT: Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SA. Nat Biotechnol. 2011, 29(7):635-43. doi: 10.1038/nbt.1899. PMCID:PMC3366591. Discovery, AIMS, and MRM datasets Discovery_Tranche_hash: b/quYtp/Q8fY6EdnRMoUEe5Jme2WHwYKLj50kWO/JvsNdVnQV6UCgTixEFP9uQiBYJo9emQVc2lRzbDQLKURot4mEXEAAAAAAAGNYQ== AIMS_Tranche_hash: dzovoZTeT+kY0bQ4/NxPDI912ib+Z0/7UM/QS+Tzn1p0qdljLshY74okkmbLgCkQLbK8/CqwnSwPYciLSQqNc70hDuEAAAAAAACjIg== MRM_Tranche_hash: WNWMJg68D/CjrNnR26osMAfjmCNGbxEMweFdZJTps7AUv8Aw9pIhsfbMehM4lGYJSIKVx6CbZS/pBCftDf8XvDuKidMAAAAAAABCMg==

SUBMITTER: Steven A. Carr

PROVIDER: MSV000078513 | MassIVE | Thu Dec 19 19:03:00 GMT 2013

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Publications

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.

Addona Terri A TA Shi Xu X Keshishian Hasmik H Mani D R DR Burgess Michael M Gillette Michael A MA Clauser Karl R KR Shen Dongxiao D Lewis Gregory D GD Farrell Laurie A LA Fifer Michael A MA Sabatine Marc S MS Gerszten Robert E RE Carr Steven A SA

Nature biotechnology 20110619 7

We developed a pipeline to integrate the proteomic technologies used from the discovery to the verification stages of plasma biomarker identification and applied it to identify early biomarkers of cardiac injury from the blood of patients undergoing a therapeutic, planned myocardial infarction (PMI) for treatment of hypertrophic cardiomyopathy. Sampling of blood directly from patient hearts before, during and after controlled myocardial injury ensured enrichment for candidate biomarkers and allo ...[more]

PMID: 21685905

Publication: 1/2

Similar Datasets

Identification of regulators of polyploidization presents therapeutic targetsfor treatment of AMKL

Project description:Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L,Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T,Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD. Cell. 2012 150:575-89. doi: 10.1016/j.cell.2012.06.032. PMCID: PMC3613864

2014-01-27 | MSV000078536 | MassIVE

Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development

Project description:Jaffe JD, Keshishian H, Chang B, Addona TA, Gillette MA, Carr SA. Mol Cell Proteomics, 2008, 7, 1952-62. Tranche_hash:XQmp4fY8N3eYKVAoPWzjkrpNr0Pe4QuyNoPVdDo0UTq2JIdui2Z//aQ4jMZnat7dDuAkhiHdErfyMgBrvWT4dQRmutgAAAAAAAA0KQ==

2013-11-22 | MSV000078504 | MassIVE

Aptamer-based proteomic profiling reveals novel candidate biomarkers of cardiovascular disease

Project description:Ngo D, Sinha S, Shen D, Kuhn E, Keyes M, Shi X, Benson M, O'Sullivan J, Keshishian H, Farrell L, Fifer MA, Vasan RS, Sabatine M, Larson MG, Carr SA, Wang TJ, Gerszten RE. Circulation 2016. Emerging proteomic technologies are beginning to permit the systematic characterization of human plasma samples. DNA-aptamer based technologies may address limitations of existing proteomic techniques, including low sample throughput, which have prevented proteomic analyses of large cohorts. We applied an aptamer-based proteomic technology that measures 1,129 proteins to identify potential novel biomarkers of cardiovascular disease. We found very early markers of myocardial injury in a robust, clinically-relevant perturbational model of planned myocardial injury, patients undergoing septal ablation for hypertrophic cardiomyopathy. We then tested whether the platform could detect novel associations between proteins and cardiovascular risk factors in individuals without overt cardiovascular disease using archived samples from the Framingham Heart Study. Further, we developed a new workflow integrating DNA-based immunoaffinity with mass spectrometry to analytically validate the specificity of aptamer findings. Our results highlight an emerging proteomics tool capable of profiling over one thousand low abundance analytes with high sensitivity and high precision, applicable both to well-phenotyped perturbational studies as well as large human cohorts.

2016-07-14 | MSV000079908 | MassIVE

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a glioblastoma target

Project description:Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA,Kung AL, Golub TR. Nat Biotech, 2009, 27, 77-83. PMCID:PMC3057643.

2013-11-21 | MSV000078499 | MassIVE

Project description:shi

| PRJEB10335 | ENA

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.

Project description: Not available

| S-EPMC3366591 | biostudies-literature

Cardiovascular genomics: a biomarker identification pipeline.

Project description: Not available

| S-EPMC5003026 | biostudies-literature

Differential gene expression is not correlated to age-related vascular pathology in aorta and mesenteric artery of Brown Norway and Fischer344xBrown Norway rats

Project description:Novel genetic pathways associated with successful and/or unsuccessful vascular aging Customized therapies for vascular disease will require matching the vessel type and genetic background of the patient. Our previous studies showed that progressive age-related vascular pathology is strain specific in the thoracic aorta (TA) and mesenteric arteries (MA) of the Brown Norway (BN) and the Fisher344/Brown Norway F1 hybrid (F1) rats. The purpose of this study was to identify novel genetic pathways associated with successful and/or unsuccessful vascular aging. TA and MA were collected from anesthetized 6, 15 and 24 month old age-matched F1 and BN rats for total RNA isolation. The gene microarrays were generated using the Affimetrix GeneChip Rat Expression 230A Array. Gene expression data was analyzed with the Ingenuity Pathway Analysis and proprietary software. Despite more pronounced age-related vascular pathology in the F1 strain, more genes were differentially expressed in the BN strain during aging. A sample of common key genes (KLB1, TRIO, HLA-C and PCP4) showed similar expression at 6 and 15 months and downregulation at 24 months in F1 vs. upregulation in BN rats. Among the top 50 canonical pathways there was only a 10 and 30% overlap, respectively, between the F1 and BN strains in MA and TA. Most of the overexpressed molecules associated with the same vascular-related biological functions are different between strains. The data suggest that age-related vascular pathology and decrement in function is both strain and vessel-dependent and different genetic programs could be employed to accomplish both normal and pathological physiological processes in conduit and resistance arteries.

2015-03-02 | GSE55612 | GEO